ImpediMed Limited (ASX: IPD), a global provider of medical technology to measure, monitor and manage fluid status in patients, has announced the U.S. commercial launch of its L-Dex ® system to aid in ...
BRISBANE, Australia & CARLSBAD, Calif.--(BUSINESS WIRE)--Publication of a new study to assess the validity of L-Dex bioimpedance spectroscopy (BIS) measurements for evaluating the effectiveness of ...
Breast Surgeons to Conduct Complimentary L-Dex Readings, Discuss Benefits of Early Lymphedema Assessment, Treatment at Susan G. Komen for the Cure, Breast Cancer Network of Strength Events At Susan G.
CARLSBAD, Calif., Dec. 15, 2022 /PRNewswire/ -- ImpediMed Limited (ASX: IPD) is pleased to announce a poster showing that breast cancer patients receiving early detection of lymphedema using ImpediMed ...
BRISBANE, Australia & SAN DIEGO--(BUSINESS WIRE)--ImpediMed (ASX:IPD) is pleased to announce today the Centers for Medicare and Medicaid Services (CMS) has published the valuation for CPT ® Category I ...
Now, a team of researchers offers supporting evidence for using Bioelectrical Impedance Analysis (BIA) ratios to assess Lymphedema. The study argues because the low frequency electronic current cannot ...
CARLSBAD, Calif. and BRISBANE, Australia, Oct. 23, 2019 /PRNewswire/ -- ImpediMed Limited (ASX: IPD), a global provider of medical technology to non-invasively measure, monitor and manage tissue ...
BAYTOWN — Breast cancer patients undergoing treatment at Houston Methodist San Jacinto Hospital now have a valuable tool at their disposal in the battle against the potentially debilitating condition ...
BAYTOWN — Breast cancer patients undergoing treatment at Houston Methodist San Jacinto Hospital now have a valuable tool at their disposal in the battle against the potentially debilitating condition ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results